Martin Shkreli's Successor at Turing Had His Own Issues in Past
- Ron Tilles, the former chairman, has flown under the radar
- Sued for fraud by investor who allegedly threatened him
Shkreli and Turing: What’s Next?
This article is for subscribers only.
The successor to Martin Shkreli, the flamboyant former executive at the center of the drug industry’s price-gouging scandals, is someone few people have ever heard of. But his past is nearly as colorful as Shkreli’s.
His name is Ron Tilles, and his peripatetic career has included allegations of fraud and illicit offshore accounts -- and his own claim that an angry investor threatened to kill him. Tilles is stepping in to lead Turing Pharmaceuticals AG, the drugmaker the two men built, following Shkreli’s arrest on securities fraud charges.